Phaseline

Companies › Umoja Biopharma

Umoja Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UB-VV111
CD19 CAR T cell therapy generated in vivo via gene therapy
CD19Phase 1Lymphoma, B-CellMar 2029
UB-VV400
CD22-directed CAR T cell therapy
CD22Phase 1Lymphoma, B CellAug 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06528301UB-VV111Phase 1Lymphoma, B-CellOncologyMar 2029
NCT07735533UB-VV400Phase 1Lymphoma, B CellOncologyAug 2031

Targets

CD19 (1) CD22 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics AstraZeneca Miltenyi Biomedicine Amgen Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.